Positive Health Online

Abstract

LAGUZZI and COLLEAGUES,  (1)Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine (F.L., A.A., U.D.F., K.L.), Karolinska Institutet, Stockholm, Sweden; (2)Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (M.M., W.S.P); (3)The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, Australia (M.M.).(4)Section of Cardiovascular Medicine, Boston Medical Center and Boston University Chobanian and Avedisian School of Medicine, MA (F.Q.);(5)Department of Nutrition (F.Q.), Boston, MA;

(6)Cardiovascular Medicine Unit, Department of Medicine Solna (B.G.), Karolinska Institutet, Stockholm, Sweden; (7)Cardiovascular Health Research Unit, Departments of Biostatistics (T.M.B.), University of Washington, Seattle; (8)Medicine (T.M.B., R.N.L., B.M.P.), University of Washington, Seattle; (9)Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia (J.K.B., A.M.H., G.G.G.); (10)Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal (A.K.B., S.J., M.B.S.); (11)German Center for Diabetes Research, Neuherberg (A.K.B., S.J., M.B.S.); (12)Harvard T.H. Chan School of Public Health (H.C.), Boston, MA; (13)Departments of Epidemiology and Public Health and Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan (Y.H., T.N.); (14)Medical Research Council Epidemiology Unit, University of Cambridge School of Clinical Medicine, UK (F.I., N.G.F., N.J.W.); (15)Institutes of Public Health and Clinical Nutrition (M. Lankinen, J.K.V., M.U.), University of Eastern Finland, Kuopio; (16)Cancer Control Research, BC Cancer Agency, Vancouver, Canada (R.A.M.); (17)School of Population and Public Health, University of British Columbia, Vancouver, Canada (R.A.M.); (18)United States Department of Agriculture/Agricultural Research Service Children's Nutrition Research Center, Baylor College of Medicine, Houston, TX (M.S., A.C.W.); (19)Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany (M.B.S.); (20)Longitudinal Study Section, National Institute on Aging, Baltimore, MD (T.T., L.F.); (21)Fatty Acid Research Institute, Sioux Falls, SD (N.T., W.S.H.); (22)Department of Population Health Nursing Science, University of Illinois - Chicago (N.T.);(23)Department of Public Health Medicine, Institute of Medicine (K.Y., H.K.), University of Tsukuba, Japan.; (24)Health Services Research and Development Center (K.Y., H.K.), University of Tsukuba, Japan; (25)Department of Family Medicine, University of California, San Diego, La Jolla (M.A.); (26)Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, The Netherlands (I.A.B.); (27)Amsterdam Public Health Research Institute, The Netherlands (I.A.B.); (28)Icelandic Heart Association, Kopavogur (G.E., V.G.); (29)Division of Human Nutrition and Health, Wageningen University and Research, The Netherlands (J.M.G., A.C.v.W.); (30)Centre for Epidemiology and Biostatistics, University of Melbourne, Victoria, Australia (A.M.H., G.G.G.); (31)Clinical Medicine, Internal Medicine (M. Laakso), University of Eastern Finland, Kuopio; (32)Kuopio University Hospital (M. Laakso), University of Eastern Finland, Kuopio; (33)Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University, Sweden (M.M., U.R); (34)Geriatric Unit, Azienda Unità Sanitaria Locale Toscana Centro, Florence, Italy (S.B.); (35)University of Michigan School of Public Health, Ann Arbor (A. Baylin); (36)Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Victoria, Australia (G.G.G.); (37)Faculty of Medicine, University of Iceland, Reykjavik (V.G.); (38)Public Health, Department of Social Medicine, Osaka University Graduate School of Medicine, Suita, Japan (H.I.); (39)Institute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan (H.I.); (40)Department of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD (W.S.P.); (41)Epidemiology (B.M.P.), University of Washington, Seattle; (42)Health Systems and Population Health (B.M.P.), University of Washington, Seattle; (43)Metabolic Analytical Services Oy, Helsinki, Finland (J.T.S.); (44)University of Helsinki, the Faculty of Medicine, Department of Public Health, Finland (J.T.S.); (45)Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis (M.Y.T.); (46)Department of Family Medicine, Seoul National University College of Medicine, and Healthcare System Gangnam Center, Seoul National University Hospital, Republic of Korea (S.W.O.); (47)Department of Internal Medicine, Sanford School of Medicine, University of South Dakota, Sioux Falls (W.S.H.); (48)The New York Academy of Medicine, New York (D.S.); (49)Food Is Medicine Institute, Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA (D.M.) investigated whether dietary intake of polyunsaturated fatty acids (PUFA) modifies the cardiovascular disease (CVD) risk associated with a family history of CVD. The researchers assessed interactions between biomarkers of low PUFA intake and a family history in relation to long-term CVD risk in a large consortium

Background

BACKGROUND: It is unknown whether dietary intake of polyunsaturated fatty acids (PUFA) modifies the cardiovascular disease (CVD) risk associated with a family history of CVD. We assessed interactions between biomarkers of low PUFA intake and a family history in relation to long-term CVD risk in a large consortium.

Methodology

Blood and tissue PUFA data from 40 885 CVD-free adults were assessed. PUFA levels ≤25th percentile were considered to reflect low intake of linoleic, alpha-linolenic, and eicosapentaenoic/docosahexaenoic acids (EPA/DHA). Family history was defined as having ≥1 first-degree relative who experienced a CVD event. Relative risks with 95% CI of CVD were estimated using Cox regression and meta-analyzed. Interactions were assessed by analyzing product terms and calculating relative excess risk due to interaction.

Results

After multivariable adjustments, a significant interaction between low EPA/DHA and family history was observed (product term pooled RR, 1.09 [95% CI, 1.02-1.16]; P=0.01). The pooled relative risk of CVD associated with the combined exposure to low EPA/DHA, and family history was 1.41 (95% CI, 1.30-1.54), whereas it was 1.25 (95% CI, 1.16-1.33) for family history alone and 1.06 (95% CI, 0.98-1.14) for EPA/DHA alone, compared with those with neither exposure. The relative excess risk due to interaction results indicated no interactions.

Conclusion

A significant interaction between biomarkers of low EPA/DHA intake, but not the other PUFA, and a family history was observed. This novel finding might suggest a need to emphasize the benefit of consuming oily fish for individuals with a family history of CVD. Conflict of interest statement: Disclosures Dr Murphy reports having worked as a consultant for Pharmavite (until 2021). The remaining authors have reported no relationships relevant to the contents of this article. Dr Psaty serves on the steering committee of the Yale Open Data Access Project, funded by Johnson and Johnson.

References

Laguzzi F(1), Åkesson A(1), Marklund M(2)(3), Qian F(4)(5), Gigante B(6), Bartz TM(7)(8), Bassett JK(9), Birukov A(10)(11), Campos H(12), Hirakawa Y(13), Imamura F(14), Jäger S(10), Lankinen M(15), Murphy RA(16)(17), Senn M(18)(19), Tanaka T(20), Tintle N(21)(22), Virtanen JK(15), Yamagishi K(23)(24), Allison M(25), Brouwer IA(26)(27), De Faire U(1), Eiriksdottir G(28), Ferrucci L(20), Forouhi NG(14), Geleijnse JM(29), Hodge AM(9)(30), Kimura H(23)(24), Laakso M(31)(32), Risérus U(33), van Westing AC(18)(29), Bandinelli S(34), Baylin A(35), Giles GG(9)(30)(36), Gudnason V(28)(37), Iso H(38)(39), Lemaitre RN(8), Ninomiya T(13), Post WS(2)(40), Psaty BM(8)(41)(42), Salonen JT(43)(44), Schulze MB(10)(11), Tsai MY(45), Uusitupa M(15), Wareham NJ(14), Oh SW(46), Wood AC(18), Harris WS(21)(47), Siscovick D(48), Mozaffarian D(49), Leander K(1); Fatty Acids and Outcomes Research Consortium (FORCE). Role of Polyunsaturated Fat in Modifying Cardiovascular Risk Associated With Family History of Cardiovascular Disease: Pooled De Novo Results From 15 Observational Studies.  Circulation; 149(4):305-316.  doi: 10.1161/CIRCULATIONAHA.123.065530. Epub Dec 4 2023 . Jan 23 2024.